ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

ACS To Accept Database On Method Of Unconventional Rx

November 26, 1993

In Brief: NCA to Hear Reports On Outstanding Investigator Awards, Defining QRA, P01 Guidelines, Gallow Work

May 6, 1983

DCCP Board Approves Concepts For Three New RFAs, Contract Recompetitions

June 4, 1982

Gene Therapy Experiments Get RDAC Okay

August 10, 1990

DCBDC Advisors Okay New Program In Breast Cancer

July 3, 1992

In Brief: Foundation Gives Georgetown $2.9 Million For Pediatric Lab, To Be Headed By Cairo

February 6, 1998